Precisio Biotix Therapeutics
Raymond Schuch is the Vice President, Director of US Operations at Precisio Biotix Therapeutics. Prior to this role, Raymond served as Vice President of Research and Director of Microbiology at ContraFect Corp. Raymond also worked as a Research Assistant Professor at The Rockefeller University. Raymond's research focuses on the discovery and development of bacteriophage lysins as therapeutic and diagnostic tools for Gram-positive bacterial pathogens. Additionally, Raymond has studied bacteriophage identification, metagenomic analysis, and the adaptive behaviors of anthrax. Raymond holds a Ph.D. in Microbiology and Immunology from Temple University.
This person is not in any teams
Precisio Biotix Therapeutics
Precisio Biotix Therapeutics is US incorporated industry leader in precision antibacterial biological solutions; specifically the identification and development of lysin and phage products to combat bacterial infections or difficult to treat bacterial issues. Products created with lysins and phages are novel precision solutions to address the declining effectiveness of existing treatments. LysiThru™,the Company's industry-leading, high-throughput lysin screening system, is capable of rapidly creating new gram-positive and gram-negative lysins for almost every pathogen. The Company has a robust pipeline of commercial products with both Rx and consumer commercial opportunities. - Multiple gram positive and gram negative systemic lysins, with a focus on skin and lung infections. - Bactelide™, a sustained release biodegradable phage product to prevent and treat topical infections - Several topical lysins with consumer-oriented uses